Company overview

Our mission

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.

The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome.

Our lead clinical compound Vonafexor (EYP001)

• Molecule: small molecule; synthetic and non-steroidal agonist of FXR (farnesoid X receptor or bile acid receptor)
• Drug profile: mainly distributed to the kidney and the liver
• Administration mode: oral (tablet), once a day
• Mode of Action: fibrolytic and anti-inflammatory
• Clinical development: supported by 11 completed clinical studies: 7 Phases 1 and 4 Phases 2a. For more details about the clinical studies
• Strength: differentiated from other FXR agonists with its beneficial effect on kidney function (eGFR), inflammation and fibrosis in liver and visceral fat (Phase 2a LIVIFY study in patients with MASH) and kidney diseases CKD and Alport syndrome (Phase 2 ALPESTRIA-1 clinical study)

History of ENYO Pharma with virus biomimetism

Our story began in 2014 when experts in virus-host protein interactions from the French Infectiology Research Center (Inserm) in Lyon, France and pharmaceutical industry executives specialized in drug development developed a unique drug discovery platform based on biomimetism inspired by viruses.